Drug patents …
… from Kazakhstan to Kalamazoo
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Find generic entry opportunities
Proactively manage your pharmacy inventory
Anticipate generic drug launch
Manage your formulary budget
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic|
|Abstract:||A synergistic pharmaceutical combination and composition are disclosed for the treatment of gastritis and peptic ulcer containing a therapeutic amount of a proton pump inhibitor such as e.g., omeprazole or lansoprazole, which increases intragastric pH, and a therapeutic amount of an acid degradable antibacterial compound such as a penicillin or a macrolide. In particular, the combination is directed to the treatment of infections caused by Helicobacter pylori by raising the bioavailability of acid degradable antibacterial compounds.|
|Inventor(s):||Eek; Arne T. (Trosa, SE), Sj ostrand; Sven Erik (S odert alje, SE)|
|Assignee:||ASTRA Aktiebolag (Sodertalje, SE)|
Patent Claim Types:|
see list of patent claims
|Use; Composition; Compound;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|African Regional IP Organization (ARIPO)||466||<subscribe>|
|African Regional IP Organization (ARIPO)||9300518||<subscribe>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.